Bioequivalence Study Of Glucotrol XL 2.5 Mg Tablets
NCT00550329 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 32
Last updated 2008-10-21
Summary
The objective of this study is to determine the bioequivalence of Glipizide GITS (Glucotrol XL) 2.5 mg tablets manufactured at the Brooklyn, New York facility versus tablets manufactured at the facility in Barceloneta, Puerto Rico.
Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
- Hyperglycemia
Interventions
- DRUG
-
Glipizide GITS
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Pfizer CT.gov Call Center · Pfizer
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2007-10-31
- Completion
- 2007-11-30
Countries
- Singapore
Study Locations
More Related Trials
-
Food Study of Glipizide and Metformin HCl Tablets 5 mg/500 mg to Metaglip® Tablets 5 mg/500 mg
NCT00648505 ·Status: COMPLETED ·Phase: PHASE1
-
A 3-fold Crossover Bioequivalence Study Between Glucobay Orally Disintegrating Tablet (ODT) and Glucobay Standard Tablet
NCT01388153 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence of a 2.5 mg Linagliptin / 500 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 500 mg Tablets Administered Together in Healthy Volunteers
NCT02221414 ·Status: COMPLETED ·Phase: PHASE1
-
A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate
NCT00740051 ·Status: COMPLETED ·Phase: PHASE3
-
Glyburide/Metformin 5 mg/500 mg Film-Coated Tablets, Fed
NCT00835991 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study of Metformin Hydrochloride Extended-Release Tablets USP 750 mg Under Fed Condition
NCT01831674 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants
NCT01068717 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence of a Fixed Dose Combination Tablet Linagliptin/Pioglitazone Compared With Its Mono-components
NCT01276327 ·Status: COMPLETED ·Phase: PHASE1
-
Fasting Study of Glipizide and Metformin HCl Tablets 5 mg/500 mg to Metaglip® Tablets 5 mg/500 mg
NCT00649454 ·Status: COMPLETED ·Phase: PHASE1
-
A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
NCT01755494 ·Status: COMPLETED ·Phase: PHASE1
-
Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Relative to Originator
NCT06233240 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Bioequivalence Study of Metformin Hydrochloride Extended Release 500 mg Tablet Versus Glucophage XR® 500 mg Tablet in Healthy Volunteers Under Fed Conditions
NCT01089179 ·Status: COMPLETED ·Phase: PHASE1
-
Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Relative to Originator
NCT06233201 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes
NCT00622284 ·Status: COMPLETED ·Phase: PHASE3
-
Bioequivalence Study of Metformin Hydrochloride Extended-Release Tablets USP 750 mg Under Fasting Condition
NCT01831661 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study to Compare Empagliflozin + Linagliptin 25 mg/5 mg Film-coated Tablets Versus Glyxambi 25 mg/ 5 mg Film-coated Tablets
NCT06932159 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence of a Linagliptin / Metformin Fixed-dose Combination (FDC) Tablet Compared With Single Linagliptin and Metformin Tablets Administered Together in Healthy Volunteers
NCT02221401 ·Status: COMPLETED ·Phase: PHASE1
-
BE Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin HCl XR Tablet Relative to a 5 mg Saxagliptin (Onglyza™) Tablet and a 500 mg Metformin HCl XR (Glifage® XR Marketed in Brazil by Merck S.A.) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States
NCT01305551 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Research Study to Assess the Mechanism By Which Glucovance, Metformin, and Glyburide Work To Control Glucose Levels In Patients With Type 2 Diabetes
NCT00035568 ·Status: COMPLETED ·Phase: PHASE4
-
Glucophage Immediate Release (GIR) China Bioequivalence Study
NCT03393208 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin Compared With the Free Combination of Empagliflozin Tablet and Linagliptin Tablet in Healthy Male and Female Subjects
NCT02758171 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes
NCT00309608 ·Status: COMPLETED ·Phase: PHASE2
-
Bioequivalence Study of Two Formulations of 500 mg Metformin Extended Release Tablet
NCT01677260 ·Status: COMPLETED ·Phase: NA
-
Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 × 500 mg Glucophage XR
NCT01192152 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence of Metformin Under Fed Conditions After Administration of Linagliptin / Metformin Fixed Dose Combination Tablet and Single Tablets
NCT01581931 ·Status: COMPLETED ·Phase: PHASE1